Form 4: RA Capital Sells Over 136K Sionna Therapeutics Shares

Sentiment:

Insider Trading Report 19 November 2025 8:43 PM

📋All filings for Sionna Therapeutics, INC

RA Capital Management and affiliated funds sold 136,351 shares of Sionna Therapeutics common stock across multiple transactions in mid-November 2025.

Worse than expectedRA Capital Management, a 10% owner and director, sold a substantial number of shares. While these sales were conducted under a Rule 10b5-1 plan, indicating pre-scheduled transactions, the divestment by a major institutional investor can still be perceived as a negative indicator for the stock.

Summary

RA Capital Management, L.P., along with its affiliated funds (RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account), sold a total of 136,351 shares of Sionna Therapeutics, Inc. common stock.
The transactions occurred on November 17, 2025, November 18, 2025, and November 19, 2025.
Sales were executed at weighted average prices ranging from $39.57 to $42.13 per share.
These sales were made pursuant to a Rule 10b5-1(c) plan, indicating pre-arranged transactions.
Following these transactions, RA Capital Management and its affiliates beneficially own a total of 9,935,361 shares indirectly through the various funds and accounts.
Peter Kolchinsky and Rajeev M. Shah, managing members of RA Capital Management GP, LLC, and Joshua Resnick, a Partner of RA Capital Management, L.P., who serves on Sionna Therapeutics' board, are among the reporting persons.

Sentiment

Score: 4

Explanation: The sale of shares by a significant institutional investor and 10% owner, even under a pre-arranged plan, can be interpreted as a slight negative signal, though the 10b5-1 plan reduces the immediate concern of market timing.

Negatives

The sale of a significant number of shares by a 10% owner and director, RA Capital Management, could be perceived as a negative signal by investors, potentially indicating a reduced conviction in the company's near-term prospects.

Future Outlook

Industry Context

Related Party Transactions

Sales of common stock by RA Capital Management, L.P. and its affiliated funds, which are 10% owners and have directors on Sionna Therapeutics' board, constitute related party transactions.

Stakeholder Impact

Shareholders may perceive the sales by a significant institutional investor as a lack of confidence, potentially leading to downward pressure on the stock price.

Key Dates

Date	Description
11/17/2025	Date of earliest reported transaction, involving multiple sales of common stock at weighted average prices of $40.2, $41.05, and $42.1.
11/18/2025	Date of reported transactions, involving multiple sales of common stock at a weighted average price of $39.57.
11/19/2025	Date of latest reported transactions, involving multiple sales of common stock at weighted average prices of $40.01 and $40.61, and the filing date of the Form 4.

Recommendation

hold

The significant sale of common stock by RA Capital Management, a 10% owner and director, is generally a bearish signal. However, the transactions were executed under a Rule 10b5-1 plan, which suggests the sales were pre-scheduled and not necessarily driven by new, adverse information. Investors should maintain a 'hold' position and monitor future company performance and insider activity for a clearer directional signal.

Keywords

Sionna Therapeutics, SION, RA Capital Management, Insider Sales, Form 4, Equity Transaction, Biotechnology, Healthcare Investment, 10b5-1 Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.